{"id":819136,"date":"2025-02-27T08:11:07","date_gmt":"2025-02-27T13:11:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"modified":"2025-02-27T08:11:07","modified_gmt":"2025-02-27T13:11:07","slug":"alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","title":{"rendered":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Feb.  27, 2025  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.\u00a0<\/p>\n<p>The company will not be hosting a teleconference in conjunction with its financial results press release.<\/p>\n<p>\n        <strong>About ALX Oncology<\/strong><br \/>\n        <br \/>ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xd5v6C1E9-uBcHiU8vZDKBj42FPqHnzI58XrkFt833RwldICNhIX3G5oM73QzpwrUPD4EJS_g6-adDOt_zM6rAL7SHbE1ki_U5-lWVqOVok=\" rel=\"nofollow\" target=\"_blank\">www.alxoncology.com<\/a> and on LinkedIn <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yihx1-QlbPrx5mmTUgv9c8ftLjfNVz9goaaPt6IbnggDkPiosqfmEKx6IqHJt7Zsu-4CxVo2bejAmgcdNYiGx85q-unpNudw_6bAHUdeqKpd1eXO9yrH7oYuHLU7wypgCAEAodCVKSj0TXTmMR1DfQ==\" rel=\"nofollow\" target=\"_blank\">@ALX Oncology<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Elhan Webb, CFA, IR Consultant<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_1W2uukiMtfHnGHaF0DyV-NjD9GD_VIq8qvuuUx4lHdTKLt4_wzI-_YEXC06ankNIuKVXnpgfCUm73hfYY0MLxsxfUiiq8ZelXN5IMvHo3I=\" rel=\"nofollow\" target=\"_blank\">ewebb@alxoncology.com<\/a><\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Audra Friis, Sam Brown, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AsjWGK2W2NgQqIrMpyK0B4rhHKmD7voIMkIFZrHqqXTMvnOHd3vs6v2KNh7SZzp5o3F6qBXLJnKdMHb13J2fc_FGIrxyzpUAQi0N1J4plMQ=\" rel=\"nofollow\" target=\"_blank\">audrafriis@sambrown.com<\/a><br \/>(917) 519-9577<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzNhMzU0YzQtODc2Yi00MWVjLTlmOWMtY2VlNGIxYmQ2NDkwLTEyMDQ0MTY=\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.\u00a0 The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819136","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.\u00a0 The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which &hellip; Continue reading &quot;ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T13:11:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\",\"datePublished\":\"2025-02-27T13:11:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"wordCount\":189,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"name\":\"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\",\"datePublished\":\"2025-02-27T13:11:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.\u00a0 The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which &hellip; Continue reading \"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T13:11:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025","datePublished":"2025-02-27T13:11:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"wordCount":189,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","name":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=","datePublished":"2025-02-27T13:11:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTcyOSM2NzgxNjMzIzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819136"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819136\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}